Eranga Haththotuwa, MD
Cardiovascular Disease · Dover, DENPI 1669477618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 770 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,012 and has fallen 52.9% since, to $1,420 in 2025.
Across 770 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Amgen$2K
- Medtronic$2K
- AstraZeneca$1K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- plus $6K from 32 others
What the payments were for
- Food & beverage$14,56298%
- Education$2722%
- Other$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,925 in reported general payments places this provider in the 80th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $570,339 |
| EvkeezaEvinacumab-Dgnb | 13 | $561,753 |
| EliquisApixaban | 357 | $415,480 |
| OpsumitMacitentan | 24 | $305,367 |
| UptraviSelexipag | 11 | $303,384 |
| EntrestoSacubitril/Valsartan | 117 | $122,082 |
| JardianceEmpagliflozin | 110 | $117,582 |
| XareltoRivaroxaban | 86 | $93,656 |
| FarxigaDapagliflozin Propanediol | 65 | $71,445 |
| BrilintaTicagrelor | 55 | $53,016 |
| Repatha SureclickEvolocumab | 54 | $49,649 |
| MultaqDronedarone Hcl | 18 | $29,336 |
| Repatha PushtronexEvolocumab | 49 | $28,385 |
| Praluent PenAlirocumab | 44 | $23,661 |
| Dofetilide | 70 | $19,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $903 | $985,819380 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $2,134 | $608,75135 claims |
| Regeneron Healthcare Solutions, Inc.Evkeeza | $233 | $561,75313 claims |
| AstraZenecaFarxiga, Brilinta | $1,164 | $124,461120 claims |
| NovartisEntresto | $1,051 | $122,082117 claims |
| Boehringer IngelheimJardiance | $840 | $117,582110 claims |
| Johnson & JohnsonXarelto | $552 | $93,65686 claims |
| Sanofi-aventis U.S. LLCMultaq | $119 | $29,33618 claims |
| Esperion Therapeutics, Inc.Nexlizet | $447 | $17,95432 claims |
| AmgenCorlanor | $1,593 | $13,43121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Dover
- Gurmeet SinghDover$9K
- Michael SheaDover$6K
- John ShuckDover$3K
- Khaled EljazzarDover$3K
- Jennifer EakinDover$2K
- Vinay HosmaneWilmington$256K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.